IND (Investigational New Drug)

Overview

An Investigational New Drug (IND) application is a formal request submitted to the U.S. Food and Drug Administration (FDA) seeking authorization to administer an unapproved drug or biological product to human subjects in a clinical trial. The IND process is the gateway between preclinical (laboratory and animal) research and human studies — no unapproved substance may be legally administered to humans in a clinical investigation without an active IND, with narrow exceptions.

The IND serves to protect human subjects by ensuring that the proposed clinical trial is based on adequate preclinical evidence of safety, that the product meets appropriate manufacturing standards, and that the study design includes sufficient safeguards.

Detailed Explanation

IND Application Components

An IND submission typically contains three core sections:

1. Animal Pharmacology and Toxicology Data — Preclinical studies demonstrating that the substance is reasonably safe for initial human testing. This includes acute and repeat-dose toxicity studies, pharmacokinetic data, and information about the substance's mechanism of action.

2. Manufacturing Information — Detailed description of the drug substance and drug product, including composition, synthesis or manufacturing process, quality control specifications, stability data, and certificate of analysis documentation. For peptides, this includes evidence of sequence identity, purity (typically by HPLC), and absence of contaminants such as endotoxins.

3. Clinical Protocol — The detailed study design, including objectives, patient selection criteria, dosing schedule, safety monitoring plan, informed consent procedures, and investigator qualifications.

IND Review Process

After submission, the FDA has 30 days to review the IND. The application is considered active unless the FDA places it on "clinical hold" due to safety concerns or deficiencies. The FDA does not "approve" an IND in the same sense as a New Drug Application — rather, it permits the clinical trial to proceed.

IND Types

• Investigator IND — Filed by an individual physician-researcher who initiates and conducts a study.
• Commercial IND — Filed by a company seeking to develop a product for eventual marketing approval.
• Emergency IND — Allows use of an investigational drug in an emergency situation that does not allow time for standard IND submission.

IND Phases

Clinical trials conducted under an IND proceed through phases:

• Phase 1 — Safety and pharmacokinetics in a small number of healthy volunteers or patients (typically 20–80 subjects).
• Phase 2 — Preliminary efficacy and dose-finding in a larger patient population (typically 100–300 subjects).
• Phase 3 — Definitive efficacy and safety in a large patient population (typically 1,000–3,000+ subjects), forming the basis for marketing approval.

Relevance to Peptide Research

The IND framework is directly relevant to understanding the regulatory status of research peptides:

• Current status — The majority of peptides discussed in the research community have not undergone IND filing and have not been tested in FDA-authorized human clinical trials. This means their safety and efficacy in humans have not been evaluated through the standard regulatory process.
• Manufacturing standards — IND-level manufacturing requires GMP (Good Manufacturing Practice) compliance, a substantially higher standard than the "research grade" purity typical of commercially available research peptides.
• Preclinical-to-clinical gap — Many peptides have promising animal data but have not completed the preclinical toxicology package required for IND submission, leaving a significant evidentiary gap.
• Compounding exception — Some peptides are available through compounding pharmacies under different regulatory frameworks, which do not require IND approval but impose their own quality and prescribing standards.

Examples

• A pharmaceutical company submits an IND to the FDA containing two-year rodent toxicology data, validated HPLC purity specifications, and a Phase 1 protocol for a novel synthetic peptide targeting tissue repair.
• A peptide widely discussed in the research community has extensive in vitro and animal data but no IND filing, meaning it has not been authorized for administration to humans in a clinical trial setting.
• An investigator IND is filed by a university researcher to conduct a small pilot study of a peptide analog in patients with a rare condition, based on five years of published preclinical data.

Related Terms

• Off-Label Use — Applies only to products that have completed the full approval process, unlike IND-stage products
• Endotoxin — A contaminant that must be below specified limits in IND-stage products
• Certificate of Analysis — Documentation of product quality required for IND submissions
• Therapeutic Index — Safety margin assessment that informs IND dosing decisions
• Biomarker — Endpoints used in IND-authorized clinical trials to assess safety and efficacy